Eurofarma Innovation and Growth Strategy
8
eurofarma
LEADERSHIP POSITION IN THE MAIN THERAPEUTIC CLASSES
Diversified Portfolio
Market Share by ATC Level I
Dec/21
% of sales 3,5% 2,8% 2,4% 2,1% 2,0% 1,9% 1,9% 1,8% 1,8% 1,8% 1,7% 1,7% 1,7% 1,6% 1,5% 1,5%
Market
position #2 #1 #1 #1
#1 #1 #1 #1 #1 #1 #2 #1 #4 #1 #3 #2 #1 #1
28.0%
44.6%
36.8%
33.8%
59.1%
45.9%
45.8%
32.4%
20.6%
25.0%
21.5%
9.4%
52.2%
29.2%
24.1%
16.1%
1,4% 1,4% 1,3% 1,2%
#1 #1 #2 #2
84.7%
56.7%
27.9%
20.8%
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10 #11
#12
#13
#14
#15
#16
#17 #18 #19
#20
R$2.8 bn
#2
37.2%
Top 20 products
as % of total revenue
Source: Retail and non-retail sales channels in R$ PPP, Dec21 | Eurofarma, Momenta and Supera;
Total combined revenue
of top 20 products
Ranking among top 20 best
anti-infective market products
TOP 20 products: #1 Enoxaparin Sodium, #2 Piperacillin/ Tazobactam, #3 Ethinylestradiol/ Gestodene, #4 Quetiapine, #5 Paroxetine, #6 Cyproterone/ Ethinylestradiol, #7 Pantoprazole, #8 Tadalafil, #9 Betamethasone, #10 Amoxicillin/ Clavulanic Acid, #11 Azithromycin, #12 Colecalciferol, #13
Hydrochlorothiazide/ Olmesartan Medoxomil, #14 Escitalopram, #15 Desvenlafaxine, #16 Sertraline, #17 Lithium, #18 Levofloxacin, #19 Ceftriaxone, #20 Heparin.
*Only retail channel (pharmacy)View entire presentation